Explore

Trendline Trendline
Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead
Trendline Trendline
Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals
Trendline Trendline
Alnylam Pharmaceuticals to Showcase Vutrisiran Data at Heart Failure 2026

Alnylam Pharmaceuticals to Showcase Vutrisiran Data at Heart Failure 2026

Alnylam Pharmaceuticals to Showcase Vutrisiran Data at Heart Failure 2026
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat

Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat

Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat
Trendline Trendline
Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement

Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement

Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Passage Bio Announces Major Workforce Reduction Following FDA Trial Design Request

Passage Bio Announces Major Workforce Reduction Following FDA Trial Design Request

Passage Bio Announces Major Workforce Reduction Following FDA Trial Design Request
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
Summit Therapeutics Faces Setback as Ivonescimab Misses Early Survival Goal in Lung Cancer Trial

Summit Therapeutics Faces Setback as Ivonescimab Misses Early Survival Goal in Lung Cancer Trial

Summit Therapeutics Faces Setback as Ivonescimab Misses Early Survival Goal in Lung Cancer Trial
Trendline Trendline
Allarity Therapeutics Advances Stenoparib Toward Phase 3 Development for Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Toward Phase 3 Development for Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Toward Phase 3 Development for Ovarian Cancer
Trendline Trendline
Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark